Bioaxone Biosciences

20 articles about Bioaxone Biosciences

• BioAxone BioSciences Announces Patent Issued for Pharmaceutical Compositions of BA-210, a Rho Inhibitor for the Treatment of Spinal Cord Injury

  6/22/2022

  BioAxone BioSciences, Inc., a clinical stage biotechnology company committed to discovering and developing drugs for neurological conditions, today announced that a new patent has been issued for BA-210, a Phase 3-ready pro-regenerative drug candidate for the treatment of spinal cord injury.

• BioAxone BioSciences Announces License of Cerebral Cavernous Malformations Drug Candidate BA-1049 and Portfolio of Rho Kinase Inhibitors to Neurelis

  6/21/2021

  BioAxone BioSciences, Inc., a biotechnology company committed to discovering and developing drugs for unmet needs of neurological conditions today announced the license of BA-1049, its innovative orally-available ROCK2 inhibitor that has promise as a therapeutic agent for the treatment of cerebral cavernous malformations (CCMs), to Neurelis, Inc.

• Neurelis Announces Acquisition Of Rights To Portfolio Of New Chemical Entity (NCE) Compounds Targeting Cerebral Cavernous Malformations, A Rare CNS Disorder

  6/21/2021

  Neurelis, Inc., announced today that it has acquired from BioAxone Biosciences, Inc.

• CORRECTING and REPLACING BioAxone BioSciences Expands Patent for Treatment of Cerebral Cavernous Malformations and Cerebral Aneurysms with Rho Kinase Inhibitors

  12/16/2019

  BioAxone BioSciences, Inc. announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO). The notice refers to a critical patent application (US 15/988,736) covering the oral drug candidate in development, BA-1049.

• BioAxone BioSciences Expands Patent for Treatment of Cerebral Cavernous Malformations and Cerebral Aneurysms with Rho Kinase Inhibitors

  12/16/2019

  Receives Notice of Allowance on Patent Protection for Orally Available ROCK2 Inhibitor

• BioAxone BioSciences Announces Publication in Translational Stroke Research of Cavernous Angioma Disease Research Article

  9/12/2019

  BioAxone BioSciences, Inc., a biotechnology company committed to applying an innovative understanding of axon regeneration and neuronal signaling to transform the lives of patients afflicted with neurotrauma or neurovascular disorders, today announced the publication in Translational Stroke Research of data indicating that BA-1049 has promise as a therapeutic agent for the treatment of Cavernous Angioma (CA)

• BioAxone BioSciences’ Scientific Advisory Board Member, Mark Bear, PhD, Receives $500,000 Beckman-Argyros Vision Research Award

  8/15/2018

  Annual Award Recognizes Transformative Breakthroughs in Vision Research

• BioAxone BioSciences Receives Notice of Allowance on Patent for Treatment of Cerebral Cavernous Malformations and Cerebral Aneurysms with Rho Kinase Inhibitors

  8/8/2018

  Further strengthens BioAxone’s patent portfolio for Rho Kinase 2 inhibitors

• BioAxone BioSciences CEO Lisa McKerracher Speaker at NeuroTrauma2018 Conference

  8/1/2018

  Platform Talk on Update on Clinical Trials in Spinal Cord Injury

• BioAxone BioSciences Receives Notice of Allowance for Composition of Matter Patent Covering Novel ROCK2 Inhibitor

  7/10/2018

  Strengthens patent portfolio of Rho Kinase 2 inhibitors

• Bioaxone Biosciences Awarded NINDS SBIR Funding For The Development Of Self-Delivering RNAi (sd-rxRNA) For The Treatment Of Spinal Cord Injury

  9/15/2017

• Bioaxone Biosciences CEO Lisa McKerracher Accepts Role Of Consortium Advisory Panelist For The Christopher Reeve Foundation

  8/10/2017

• Bioaxone Biosciences Announces Peer-Reviewed Research Article On Axon Regeneration Published In Frontiers Journal Series

  7/19/2017

• Bioaxone Biosciences Announces New Hires To Support Investigational New Drug Filing

  5/11/2017

• Bioaxone Biosciences Continues Plans For Growth With Manufacturing Contract

  5/2/2017

• Bioaxone Biosciences Appoints Dr. Catherine Sohn To Lead Corporate Development

  4/21/2017

• Bioaxone Biosciences Announces NIH/SBIR Fast Track Grant To Develop BA-1049 For Treatment Of Cerebral Cavernous Malformation/Angioma

  2/8/2016

• Bioaxone Biosciences Announces Publication of Cethrin&#0153 Spinal Cord Injury Clinical Trial Analysis of Treatment Outcomes in the Journal of Neurotrauma

  9/25/2013

• Nordion International and Bioaxone Biosciences Reach an Agreement to Settle Claims

  9/24/2013

• Bioaxone Biosciences Celebrates Official Opening of Clinical and Research Operations in Cambridge, Mass.

  11/28/2012